FibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

by NASDAQ Market News April 12, 2021

NASDAQ Market News
Click here to email author

OpGen Announces Results from Successful Webinar on Bacterial Pneumonia Co-infections in COVID-19 Patients

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet

Ads